Liquidia (NASDAQ:LQDA) Shares Up 9.1% – Should You Buy?

Liquidia Corporation (NASDAQ:LQDA) traded up 9.1% during trading on Friday . The stock traded as high as $34.57 and last traded at $34.6550. 1,890,581 shares were traded during mid-day trading, an increase of 14% from the average session volume of 1,665,680 shares. The stock had previously closed at $31.76.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Company preliminary results show strong commercial traction — estimated Q4 YUTREPIA net sales ~ $90.1M and full‑year 2025 sales ~ $148.3M, with >$30M positive cash flow in Q4 and ~$190.7M cash on hand. Preliminary Full‑Year 2025 Net Sales and Corporate Update
• Positive Sentiment: Strong commercial adoption metrics: >2,800 unique prescriptions since launch, >2,200 patients started, ~85% prescription‑to‑start conversion and expanding prescriber base — supporting durable revenue growth expectations. QuiverQuant Summary of Commercial Metrics
• Positive Sentiment: Wall Street reaction: recent analyst upgrades/coverage (including a “Buy” and higher price targets) and the stock hitting a 52‑week high have pushed sentiment and buying interest. Analyst Upgrade / 52‑Week High Note
• Neutral Sentiment: Valuation and coverage pieces are re‑rating the story after the commercial debut; these analyses help explain multiple expansion but depend on sustained sales. Valuation Review
• Neutral Sentiment: Management plans multiple 2026 clinical studies (YUTREPIA and L606) and will present at the J.P. Morgan Healthcare Conference — potential longer‑term catalysts if trials progress. Coverage of Q4 Sales Beat & Pipeline Plans
• Negative Sentiment: Legal overhang: ongoing patent litigation with United Therapeutics seeks injunctive relief that could disrupt YUTREPIA sales if decisions go against Liquidia — a material binary risk. Litigation Mention in Company Release
• Negative Sentiment: Corporate governance/overhang: notable insider selling activity has been reported in recent months, which some investors view as a cautionary signal despite strong sales. Insider Trading Notes
• Negative Sentiment: Numbers are preliminary and unaudited — final audited results (due in February) could differ and introduce short‑term volatility. Caution on Preliminary Results

Wall Street Analyst Weigh In

Several research firms have recently issued reports on LQDA. Needham & Company LLC increased their price objective on shares of Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Wednesday, October 8th. BTIG Research reaffirmed a “buy” rating on shares of Liquidia in a research report on Friday. Finally, HC Wainwright increased their target price on Liquidia from $35.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.56.

Liquidia Stock Up 12.9%

The company has a market capitalization of $3.12 billion, a price-to-earnings ratio of -24.90, a P/E/G ratio of 1.19 and a beta of 0.48. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The firm has a 50 day moving average price of $31.71 and a two-hundred day moving average price of $25.15.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The business had revenue of $54.34 million for the quarter, compared to analysts’ expectations of $18.86 million. The business’s revenue for the quarter was up 1106.7% on a year-over-year basis. As a group, sell-side analysts expect that Liquidia Corporation will post -1.51 earnings per share for the current year.

Insider Activity at Liquidia

In other Liquidia news, CFO Michael Kaseta sold 11,630 shares of the stock in a transaction on Monday, October 13th. The shares were sold at an average price of $23.41, for a total transaction of $272,258.30. Following the transaction, the chief financial officer directly owned 352,646 shares in the company, valued at $8,255,442.86. This represents a 3.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Russell Schundler sold 7,839 shares of the firm’s stock in a transaction on Monday, October 13th. The stock was sold at an average price of $23.41, for a total transaction of $183,510.99. Following the transaction, the general counsel directly owned 576,017 shares of the company’s stock, valued at approximately $13,484,557.97. This represents a 1.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 169,644 shares of company stock worth $4,500,450. 26.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Liquidia

Large investors have recently modified their holdings of the stock. Farallon Capital Management LLC increased its holdings in Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares during the last quarter. TCG Crossover Management LLC acquired a new position in shares of Liquidia in the 3rd quarter worth approximately $38,887,000. Caprock Group LLC bought a new stake in shares of Liquidia in the 3rd quarter valued at approximately $37,114,000. Tyro Capital Management LLC acquired a new stake in shares of Liquidia during the 2nd quarter valued at approximately $15,473,000. Finally, CenterBook Partners LP lifted its stake in Liquidia by 811.7% during the second quarter. CenterBook Partners LP now owns 1,103,850 shares of the company’s stock worth $13,754,000 after purchasing an additional 982,778 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).